Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastroenterol ; 26(2): 134-153, 2020 Jan 14.
Article in English | MEDLINE | ID: mdl-31969776

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer with a poor prognosis. Previous studies revealed that the tumor microenvironment (TME) plays an important role in HCC progression, recurrence, and metastasis, leading to poor prognosis. However, the effects of genes involved in TME on the prognosis of HCC patients remain unclear. Here, we investigated the HCC microenvironment to identify prognostic genes for HCC. AIM: To identify a robust gene signature associated with the HCC microenvironment to improve prognosis prediction of HCC. METHODS: We computed the immune/stromal scores of HCC patients obtained from The Cancer Genome Atlas based on the ESTIMATE algorithm. Additionally, a risk score model was established based on Differentially Expressed Genes (DEGs) between high- and low-immune/stromal score patients. RESULTS: The risk score model consisting of eight genes was constructed and validated in the HCC patients. The patients were divided into high- or low-risk groups. The genes (Disabled homolog 2, Musculin, C-X-C motif chemokine ligand 8, Galectin 3, B-cell-activating transcription factor, Killer cell lectin like receptor B1, Endoglin and adenomatosis polyposis coli tumor suppressor) involved in our risk score model were considered to be potential immunotherapy targets, and they may provide better performance in combination. Functional enrichment analysis showed that the immune response and T cell receptor signaling pathway represented the major function and pathway, respectively, related to the immune-related genes in the DEGs between high- and low-risk groups. The receiver operating characteristic (ROC) curve analysis confirmed the good potency of the risk score prognostic model. Moreover, we validated the risk score model using the International Cancer Genome Consortium and the Gene Expression Omnibus database. A nomogram was established to predict the overall survival of HCC patients. CONCLUSION: The risk score model and the nomogram will benefit HCC patients through personalized immunotherapy.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Hepatocellular/mortality , Liver Neoplasms/mortality , Models, Genetic , Tumor Microenvironment/genetics , Aged , Antineoplastic Agents, Immunological/pharmacology , Antineoplastic Agents, Immunological/therapeutic use , Biomarkers, Tumor/antagonists & inhibitors , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/immunology , Databases, Genetic/statistics & numerical data , Datasets as Topic , Female , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic/immunology , Humans , Kaplan-Meier Estimate , Liver/immunology , Liver/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/genetics , Liver Neoplasms/immunology , Male , Middle Aged , Neoplasm Staging , Nomograms , Precision Medicine/methods , ROC Curve , Risk Assessment/methods , Treatment Outcome , Tumor Microenvironment/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...